JANX vs OKTA · rev $10.3M vs P/E 84, rev $1.57B
Janux Therapeutics Inc (JANX) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
JANX currently screens at market cap $1.49B. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the JANX and OKTA stock pages for the full models.
Not investment advice.